MN Ramasamy
Oxford University Hospitals NHS Trust, University of Oxford, University of Cambridge
Research areas: Medicine · Infectious Diseases · SARS-CoV-2 and COVID-19 Research · Bacterial Infections and Vaccines · COVID-19 Clinical Research Studies
0000-0002-2119-951X
About
Maheshi received her undergraduate medical training at Christ’s College, Cambridge. She subsequently trained as a junior doctor in Infectious Diseases and General Internal Medicine in Oxford, London and Australia and obtained a DPhil from Wadham College, Oxford. As Professor of Infection & Vaccinology at the Oxford Vaccine Group, Maheshi’s research focuses on developing novel vaccines for emerging pathogens including Lassa fever virus and invasive non-typhoidal Salmonella. She has a particular interest in controlled human infection models, both as a tool to understand the pathophysiology of disease and to inform immunogen design.
She leads the UK National Immunisation Schedule Evaluation Consortium and is a member of the Joint Committee on Vaccination and Immunisation (JCVI), advising the UK Department of Health and Social Care on immunisation policy.
Maheshi has a deep interest in medical education and is the Deputy Director of the Graduate Entry Medicine programme at the University of Oxford and a Fellow by Special Election at Magdalen College. She continues to practice clinically as a Consultant Physician at Oxford University Hospitals NHS Foundation Trust.
Employment
-
Oxford University Hospitals NHS Trust Consultant Physician2018 - Present
-
University of Oxford Professor of Infection & Vaccinology
Education
-
University of Cambridge MA Medical and Veterinary Sciences Tripos1995 - 1998
Projects & Funding
-
Protection Against Invasive NTS Disease (PAINTS) - correlates of protection towards vaccine licensure Wellcome Trust Ltd2024 - 2027
-
PADOVAX - Lassa Coalition for Epidemic Preparedness Innovations2024 - 2028
-
National Immunisation Schedule Evaluation Consortium (NISEC) II National Institute for Health and Care Research2023 - 2026
-
A single-blind, randomised, phase II multi-centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules in adolescents (COMCOV-3) National Institute for Health and Care Research2021 - 2024
-
Covid-19 heterologous prime/boost vaccine study National Institute for Health and Care Research2020 - 2023
-
Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa Horizon 20202019 - 2026
-
National Immunisation Schedule Evaluation Consortium (NISEC) National Institute for Health and Care Research2017 - 2023
Publications (90)
- Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20) compared with PCV13 given in homologous schedules at 3 months and 12 months (‘1+1’ schedule) and 2 months, 4 months and 12 months (‘2+1’ sc… Save
- ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses Save
- Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol Save
- Enablers and barriers to participation in vaccine trials: a narrative synthesis Save
- Securing the Future of Immunisation: ESCMID’s Vision Save
- Securing the Future of Immunisation: ESCMID’s Vision Save
- Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis Save
- Protocol for a phase IV, Experimental Human Pneumococcal Challenge (EHPC) model to investigate Streptococcus pneumoniae serotype 3 (SPN3) colonisation following PCV15, a double-blind randomised controlled trial in healthy participants aged 18-50 years in… Save
- Safety, efficacy, and immunogenicity of a Salmonella Paratyphi A vaccine Save
- Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial Save
- MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines Save
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY) Save
- Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol Save
- Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY) Save
- Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Save
- Identifying and reducing risks of neurological complications associated with vaccination Save
- Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial Save
- Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 … Save
- Synbiotics in post-acute COVID-19 syndrome—a potential new treatment framework? Save
- The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops Save